Phase 2/3Active, not recruitingNCT03941132
UST1D2: Ustekinumab phase-2/3 in adults with recent-onset T1D
Active phase-2/3 trial testing ustekinumab in adults with recent-onset T1D, following earlier pilot and adolescent signals.
Primary endpoints
- C-peptide preservation and safety endpoints per protocol
Results so far
No results posted as of the June 2026 registry update reviewed here.
The full picture
UST1D2 is the adult follow-on trial that will determine whether ustekinumab's adolescent C-peptide signal generalizes.